# Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

> **NCT01209156** · PHASE1 · COMPLETED · sponsor: **Institute for Neurodegenerative Disorders** · enrollment: 11 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** [18F] PBR111

## Key facts

- **NCT ID:** NCT01209156
- **Lead sponsor:** Institute for Neurodegenerative Disorders
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2013-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01209156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01209156, "Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01209156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*